TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05802979
Drug: Adjuvants, Anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: testing the effect of adding ketamine versus neostigmine to the analgesic efficacy of serratus anterior plane block in modified radical mastectomy surgeries
Study: NCT05712707
Drug: BXCL501 (180 micrograms)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
Study: NCT05712707
Drug: BXCL501 (240 micrograms)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Throughout the 7-day inpatient study (Figure 1; Table 1), participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, double-dummy design.
Study: NCT04868045
Drug: levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients maintenance dose of levothyroxine will be taken throughout the study. On Day~1 and Day 5, the levothyroxine will be taken after the TRH test is complete. On Days 2- 4, the levothyroxine will be taken in the morning.
Study: NCT05915013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo
Study: NCT06759753
Drug: Aleeto
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the groups, patients would be treated with Aleeto via intravenous injection, and the specific dosage of Aleeto will depend on the grouping.
Study: NCT05463367
Drug: Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet
Normalized name: carbidopa-levodopa 25 mg-100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose of carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
Study: NCT05463367
Drug: Naproxen 500 Mg
Normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive a single dose of naproxen 500mg alongside carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
Study: NCT05463367
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be pre-screened in regards to their opioid medication. They will receive a single dose of their opioid dose, when appropriate. This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
Study: NCT06759753
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with the same dosage form, odor and color as Aleeto was administered in the same way and course of treatment.
Study: NCT06040268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA134a inhaler
Study: NCT04767373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% sodium chloride \[NaCL\]) solution
Study: NCT05578092
Drug: MRTX0902
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOS1 inhibitor
Study: NCT06454721
Drug: [89Zr]Zr-DFO-BIIB080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT06454721
Drug: BIIB080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT04485104
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution
Study: NCT05064488
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive rosuvastatin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
Study: NCT06218303
Drug: Aromatase Inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: A type of hormone therapy for cancer used to inhibit aromatase to treat a hormone-related breast cancer.
Study: NCT05231785
Drug: ALN-APP
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ALN-APP will be administered intrathecally (IT)
Study: NCT05231785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered IT
Study: NCT05626010
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen 1g iv dripping at end of surgery
Study: NCT05626010
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 300mg iv dripping at end of surgery
Study: NCT05974410
Drug: AVM0703
Approvals — FDA: no, EMA: no, PMDA: no
Description: small molecule immunomodulatory drug
Study: NCT05974410
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: physiologic circadian glucocorticoid
Study: NCT05974410
Drug: Proton pump inhibitor
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05896137
Drug: CS0159
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral QD
Study: NCT06060782
Drug: Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: All enrolled patients received TCCA conditioning regimen（） before auto-HSCT:~Thiotepa 5mg/kg, -8, -7 days Cyclophosphamide 40mg/kg, -6, -5 days Cladribine 5mg/m2, -4, -3, -2 days Cytarabine 2g/m2, -4, -3, -2 days
Study: NCT05879822
Drug: INCB099280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm description
Study: NCT05895162
Drug: JUVIA zinc containing vaginal gel treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women receive a single oral dose of fluconazole (150mg) followed by treatment with JUVIA zinc containing vaginal gel (daily for 2 weeks and twice per week thereafter).
Study: NCT05030545
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After baseline cardiac imaging with PET and echocardiogram, participants will be treated with eplerenone for 6 months at a starting dose of 50mg daily and up to a maximally tolerated dose of 100mg daily, followed by repeat imaging with PET and echocardiogram.
Study: NCT06274905
Drug: Aqueous cream BP
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous cream
Study: NCT04830644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally twice a day
Study: NCT06434038
Drug: Low Dose Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intranasally at 40 IU
Study: NCT06434038
Drug: High Dose Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Intranasally at 80 IU
Study: NCT06781385
Drug: Intra-arterial Saline
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-time dose of intra-arterial saline post-thrombectomy
Study: NCT00000626
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05702073
Drug: INS068 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
Study: NCT05035641
Drug: AND017
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2
Study: NCT05035641
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, 3 times per week
Study: NCT04668222
Drug: Yu-Ping-Feng formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yu-Ping-Feng formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08255). The intake dosage is 5g twice daily.
Study: NCT05794243
Drug: LY3493269
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05794243
Drug: Salcaprozate Sodium (SNAC)
Normalized name: salcaprozate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04668222
Drug: Xiang-Sha-Liu-Jun formula
Normalized name: Calagel Reformulated Jun 2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiang-Sha-Liu-Jun formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08252). The intake dosage is 5g twice daily.
Study: NCT04668222
Drug: Placebo for Deficiency of Qi and Yang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for the group of deficiency of Qi and Yang is composed of 5% Yu-Ping-Feng formula+Xiang-Sha-Liu-Jun formula
Study: NCT04668222
Drug: Placebo for Deficiency of Qi and Yin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for the group of deficiency of Qi and Yin is composed of 5% Yu-Ping-Feng formula+Liu-Wei-Di-Huang formula
Study: NCT05889845
Drug: Candin, Intradermal Solution
Normalized name: Candin, intradermal solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at the base of the selected wart
Study: NCT05889845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at the base of the selected wart
Study: NCT05274802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo before Breakfast
Study: NCT05274802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of placebo up to two times daily
Study: NCT06435221
Drug: Cytisinicline
Normalized name: cytisinicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated oral tablets containing 3 mg cytisinicline
Study: NCT05518123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo with every other day dosing during DBT phase
Study: NCT06015308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection in abdomen, outer thigh, or upper arm
Study: NCT05538247
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate release oral capsules 50 mg, 3 times a day for 6 days
Study: NCT05538247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 250 mg capsules that contains no active study ingredient orally twice daily for 14 days
Study: NCT05434312
Drug: TGRX-678
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are given TGRX-678 tablets orally at one of the dose levels as pre-determined for the dose escalation sequence.
Study: NCT05675605
Drug: TY-1091
Approvals — FDA: no, EMA: no, PMDA: no
Description: TY-1091(10mg,100mg) , once a day, oral administration Dose level is from 20mg to 800mg
Study: NCT05379829
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered 3 doses s.c. Q4W.
Study: NCT04656275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05648656
Drug: TXA Nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization with TXA 500mg/ 5mL 8 hourly for 2 days plus standard care of therapy
Study: NCT06413433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, taken once daily
Study: NCT05561010
Drug: Intra-articular injection of placebo in the knee joint
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 participants will be allocated to the placebo arm.
Study: NCT06061718
Drug: iDose TR
Normalized name: iDose TR
Approvals — FDA: no, EMA: no, PMDA: no
Description: anchored intracameral implant containing travoprost
Study: NCT06432647
Drug: ATH-1105
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATH-1105 in oral form. Participants will be administered ATH-1105 once in Part A and once daily for 10 days in Part B.
Study: NCT06432647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in oral form. Participants will be administered Placebo once in Part A and once daily for 10 days in Part B.
Study: NCT04649411
Drug: standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered per the approved label and at the Investigator's discretion
Study: NCT05509946
Drug: Single dose of celecoxib 400 mg and pregabalin 150 mg
Normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of celecoxib 400 mg and pregabalin 150 mg
Study: NCT05509946
Drug: Repeated dose of celecoxib 200 mg and pregabalin 75 mg
Normalized name: celecoxib 200 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repeated dose of celecoxib 200 mg and pregabalin 75 mg started 3 days before surgery
Study: NCT05509946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06800157
Drug: Drug: LW402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered BID
Study: NCT06800157
Drug: Other: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match LW402 administered BID
Study: NCT06800196
Drug: KNT-0916
Approvals — FDA: no, EMA: no, PMDA: no
Description: • KNT-0916 is an oral inhibitor of FGFR2.
Study: NCT06314620
Drug: Heparin saline lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with intercostal chest catheter who underwent normal saline flushing with heparin saline lock
Study: NCT04722653
Drug: NNC0194-0499
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 single dose administered subcutaneously (s.c. - under the skin)
Study: NCT04722653
Drug: Placebo (NNC0194-0499 )
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 single dose administered subcutaneously (s.c. - under the skin).
Study: NCT05497700
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus injection of either 6 mcg norepinephrine to keep mean arterial blood pressure above 65 mm Hg
Study: NCT05573373
Drug: Targeted Therapy Agent
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage and protocol of the drug were carried out according to the description.
Study: NCT05187403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye-drops
Study: NCT04826003
Drug: RO7122290
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7122290 will be administered using a QW (Part I) or Q3W (Part I or Part II) schedule in combination with 100 mg cibisatamab Q3W with obinutuzumab pre-treatment. The maximum dose of RO7122290 to be explored in combination with cibisatamab with obinutuzumab pre-treatment in this study is 500 mg for the QW dosing interval (Part I) or 1500 mg for the Q3W dosing interval (Part I or Part II).
Study: NCT05051150
Drug: Epinephrin 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: epinephrine infusion rate of 0.03 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
Study: NCT06247956
Drug: Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab: Specified dose on specified days. Oxaliplatin Injection: Specified dose on specified days. Capecitabine Tablets: Specified dose on specified days. Paclitaxel Injection: Specified dose on specified days. Cisplatin Injection: Specified dose on specified days.
Study: NCT04711252
Drug: AZD9833
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage formulation: AZD9833 tablets will be administered orally
Study: NCT05085197
Drug: STSA-1005 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT05085197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT05256017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administration of placebo (3 tablets of 320 mg) on Day 1
Study: NCT06309472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo capsule at night, escalated to 2 capsules after 4 weeks if \<20 percent improvement in depression from baseline. Total treatment duration 12 weeks.
Study: NCT06457464
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination regimens including VCD (Velcade, cyclophosphamide, and dexamethasone ) or (MP) combination (melphalan and prednisolone) or VRD (Velcade, lenalidomide, dexamethasone) or VDT (Velcade, thalidomide, dexamethasone) or CRD (Cyclophosphamide, lenalidomide, dexamethasone ) or CDT (Cyclophosphamide, thalidomide, dexamethasone)
Study: NCT06339021
Drug: DAPT de-escalation
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel 30 days after DES implantation
Study: NCT06339021
Drug: default DAPT regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and ticagrelor 30 days after DES implantation
Study: NCT06282588
Drug: Zoladex 3.6Mg Implant
Normalized name: Zoladex 3.6mg Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mg, subcutaneous use
Study: NCT06282588
Drug: Decapeptyl sustained release 22.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5 mg, intramusculair injection
Study: NCT06282588
Drug: Decapeptyl sustained release 11.25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.25 mg, intramusculair injection
Study: NCT06282588
Drug: Depo-Eligard 45 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg, subcutaneous use
Study: NCT06282588
Drug: Depo-Eligard 22.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5 mg, subcutaneous use
Study: NCT06282588
Drug: Depo-Eligard 7.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg, subcutaneous use
Study: NCT05852587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be administered by the BWH investigational drug services. The placebo will be composed of cellulose microcrystal.
Study: NCT04609111
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month prasugrel monotherapy followed by clopidogrel monotherapy
Study: NCT04744571
Drug: aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate- limiting medication (i.e. Beta- blocker or rate-limiting calcium antagonist) where appropriate. Anti- anginal therapy should be used if the patients have symptom.
Study: NCT05968937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal suppository composed of Supposibase F daily per vagina
Study: NCT05867251
Drug: AVZO-021
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVZO-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with advanced solid tumors with CDK2 dependency (1A), CCNE1 amplified solid tumors (2A), HR+/HER2- BC (1B1-1B5, 2B1-2B5) and CCNE1 amplified EOC (1C, 2C)
Study: NCT05539833
Drug: KSH01 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCR-T cell injection
Study: NCT02873468
Drug: Florence 30 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL, oral, twice a day.
Study: NCT02873468
Drug: Florence 60 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL, oral, twice a day.
Study: NCT02873468
Drug: Florence 90 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL, oral, twice a day.
Study: NCT05125016
Drug: REGN4336
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once weekly (QW) by subcutaneous (SC) injection, or intravenous (IV) infusion
Study: NCT06211634
Drug: HMB-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB-001 is a bispecific antibody being developed as a prophylactic treatment option to prevent and reduce bleeding events in patients with Glanzmann thrombasthenia.
Study: NCT05445934
Drug: FB2001
Approvals — FDA: no, EMA: no, PMDA: no
Description: FB2001 for injection will be reconstituted with 100 mL of normal saline prior to intravenous infusion. FB2001 will be administered by IV infusion over approximately 60 minutes.
Study: NCT05003895
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily x 3 doses on Day -3, -2, -1 300 mg/m2 IV infusion (200 mg/m2 in Dose Level -1)
Study: NCT05445934
Drug: FB2001 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be reconstituted with 100 mL of normal saline prior to intravenous infusion. Placebo will be administered by IV infusion over approximately 60 minutes.
Study: NCT06584812
Drug: Tiprogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: Dose 1 Tiprogrel, loading dose of Tiprogrel followed by daily maintenance dose until Day 8.
Study: NCT06584812
Drug: Tiprogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 2: Dose 2 Tiprogrel ; loading dose of Tiprogrel followed by daily maintenance dose until Day 8.
Study: NCT04195633
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06710600
Drug: Single oral dose of selected medicines, respectively
Approvals — FDA: no, EMA: no, PMDA: no
Description: amiodarone (Amiodaron Arcana) 200mg, diclofenac (Diclobene) 100mg, hydrochlorothiazide (HCT G.L) 25mg, pantoprazole (Pantoloc) 40mg, voriconazole (Voriconazol Aristo®) 200mg
Study: NCT06710600
Drug: Single oral dose of selected medicines, respectively
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetylsalicylic acid (ASS Genericon) 500mg, doxycycline (Doxybene) 200mg, enalapril (Enalapril ratiopharm) 10mg, furosemide (Lasix) 40mg, verapamil (Verapabene) 80mg
Study: NCT06043323
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV (vein)
Study: NCT06043323
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT06704932
Drug: SAR446959
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection
Study: NCT06704932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection
Study: NCT05211401
Drug: Placebo arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm: 1 bag of 100 ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.